Download MendeleyDiscovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
Kuttruff, C.A., Fleck, M., Carotta, S., Arnhof, H., Bretschneider, T., Dahmann, G., Gremel, G., Grube, A., Handschuh, S., Heimann, A., Hofmann, M.H., Impagnatiello, M.A., Nar, H., Rast, G., Schaaf, O., Schmidt, E., Oost, T.(2023) J Med Chem 66: 9376-9400
- PubMed: 37450324
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00510
- Primary Citation of Related Structures:
8P01 - PubMed Abstract:
Activating the stimulator of interferon genes (STING) pathway with STING agonists is an attractive immune oncology concept to treat patients with tumors that are refractory to single-agent anti-PD-1 therapy. For best clinical translatability and broad application to cancer patients, STING agonists with potent cellular activation of all STING variants are desired. Novel cyclic dinucleotide (CDN)-based selective STING agonists were designed and synthesized comprising noncanonical nucleobase, ribose, and phosphorothioate moieties. This strategy led to the discovery of 2',3'-CDN 13 (BI 7446), which features unprecedented potency and activates all five STING variants in cellular assays. ADME profiling revealed that CDN 13 has attractive drug-like properties for development as an intratumoral agent. Injection of low doses of CDN 13 into tumors in mice induced long-lasting, tumor-specific immune-mediated tumor rejection. Based on its compelling preclinical profile, BI 7446 has been advanced to clinical trials (monotherapy and in combination with anti-PD-1 antibody).
Organizational Affiliation:
Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riss, Germany.
